Stockscreener 앱 받기
0.041
141.18%
0.024
Galera Therapeutics Inc 주식(GRTX)의 최신 뉴스
Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia
Galera Sets Deadlines for 2026 Combined Annual Meeting - tipranks.com
Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView
Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan
Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView
Galera Therapeutics (GRTX) exits radiotherapy, bets on pan-NOS breast cancer drug - Stock Titan
GRTX (Galera Therapeutics) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN
GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks
Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan
Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
Mark Bachleda takes the helm at Eyconis - BioCentury
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Galera Therapeutics faces Nasdaq delisting - Investing.com
Galera Therapeutics set to shut down one year after devastating FDA rejection - The Business Journals
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
0.49%
1.47%
자본화:
|
볼륨(24시간):